下肢骨肿瘤假体置换术后预防性静脉抗生素方案比较:一项随机临床试验
这项在12个国家48个中心开展的随机优效性试验纳入604例下肢骨肿瘤切除假体置换患者,比较术后5天与1天预防性静脉头孢菌素方案。结果显示,5天组手术部位感染率为15.0%,1天组为16.7%,两组无显著差异(HR 0.93,95%CI 0.62-1.40,P=0.73);5天组抗生素相关并发症显著更多(5.1% vs 1.6%,HR 3.24,95%CI 1.17-8.98,P=0.02)。
要点
- 术后5天预防性静脉抗生素方案未能显著降低下肢骨肿瘤假体置换术后1年内手术部位感染率。
- 5天方案组抗生素相关并发症发生率为5.1%,显著高于1天方案组的1.6%。
- 其他次要结局包括非计划再手术、肿瘤学和功能结局及死亡率在两组间无显著差异。
核心结论
- 本随机临床试验未能证实术后5天静脉抗生素方案在预防下肢骨肿瘤假体置换术后手术部位感染方面优于1天方案。
- 5天方案组抗生素相关并发症显著更多。
研究设计与样本
- 随机临床优效性试验,于2013年1月1日至2019年10月29日在12个国家的48个临床中心开展。
- 纳入原发骨肿瘤或侵犯股骨或胫骨的软组织肉瘤或股骨或胫骨寡转移骨病、预期生存至少1年、需切除及假体置换手术的患者。
- 共入组611例患者,排除7例不符合条件者,最终分析纳入604例。
- 患者随机分配至术后5天方案组(293例)或1天方案组(311例),患者、照护者和结局评估者均对治疗方案设盲。
主要发现
- 5天方案组44例(15.0%)发生手术部位感染,1天方案组52例(16.7%)发生手术部位感染(风险比0.93;95%CI 0.62-1.40;P=0.73)。
- 5天方案组15例(5.1%)发生抗生素相关并发症,1天方案组5例(1.6%)发生抗生素相关并发症(风险比3.24;95%CI 1.17-8.98;P=0.02)。
- 其他次要结局在治疗组间无显著差异。
关键数值与推荐
- 主要结局为术后1年内根据美国疾病控制与预防中心标准分类的手术部位感染(浅表切口、深部切口或器官间隙)。
- 预防性静脉头孢菌素(头孢唑林或头孢呋辛)从皮肤闭合后8小时内开始,此后每8小时给药一次。
- 随机分配至1天方案组的患者在剩余4天接受相同剂量的生理盐水每8小时一次。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The use of perioperative, prophylactic, intravenous antibiotics is standard practice to reduce the risk of surgical site infection after oncologic resection and complex endoprosthetic reconstruction for lower extremity bone tumors. However, evidence guiding the duration of prophylactic treatment remains limited. OBJECTIVE: To assess the effect of a 5-day regimen of postoperative, prophylactic, intravenous antibiotics compared with a 1-day regimen on the rate of surgical site infections within 1 year after surgery. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical superiority trial was performed at 48 clinical sites in 12 countries from January 1, 2013, to October 29, 2019. The trial included patients with a primary bone tumor or a soft tissue sarcoma that had invaded the femur or tibia or oligometastatic bone disease of the femur or tibia with expected survival of at least 1 year who required surgical management by excision and endoprosthetic reconstruction. A total of 611 patients were enrolled, and 7 were excluded for ineligibility. INTERVENTIONS: A 1- or 5-day regimen of postoperative prophylactic intravenous cephalosporin (cefazolin or cefuroxime) that began within 8 hours after skin closure and was administered every 8 hours thereafter. Those randomized to the 1-day regimen received identical saline doses every 8 hours for the remaining 4 days; patients, care providers, and outcomes assessors were blinded to treatment regimen. MAIN OUTCOMES AND MEASURES: The primary outcome in this superiority trial was a surgical site infection (superficial incisional, deep incisional, or organ space) classified according to the criteria established by the Centers for Disease Control and Prevention within 1 year after surgery. Secondary outcomes included antibiotic-related complications, unplanned additional operations, oncologic and functional outcomes, and mortality. RESULTS: Of the 604 patients included in the final analysis (mean [SD] age, 41.2 [21.9] years; 361 [59.8%] male; 114 [18.9%] Asian, 43 [7.1%] Black, 34 [5.6%] Hispanic, 15 [2.5%] Indigenous, 384 [63.8%] White, and 12 [2.0%] other), 293 were randomized to a 5-day regimen and 311 to a 1-day regimen. A surgical site infection occurred in 44 patients (15.0%) allocated to the 5-day regimen and in 52 patients (16.7%) allocated to the 1-day regimen (hazard ratio, 0.93; 95% CI, 0.62-1.40; P = .73). Antibiotic-related complications occurred in 15 patients (5.1%) in the 5-day regimen and in 5 patients (1.6%) allocated to the 1-day regimen (hazard ratio, 3.24; 95% CI, 1.17-8.98; P = .02). Other secondary outcomes did not differ significantly between treatment groups. CONCLUSIONS AND RELEVANCE: This randomized clinical trial did not confirm the superiority of a 5-day regimen of postoperative intravenous antibiotics over a 1-day regimen in preventing surgical site infections after surgery for lower extremity bone tumors that required an endoprosthesis. The 5-day regimen group had significantly more antibiotic-related complications. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01479283.
引用
- Ghert M, Schneider P, Guyatt G, et al. Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors: A Randomized Clinical Trial. JAMA Oncol. 2022. PMID: 34989778. doi:10.1001/jamaoncol.2021.6628
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。